SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of an advertisement prepared by ICN Pharmaceuticals,
Inc. and appearing in the May 23, 2002 edition of the Wall Street Journal.
ICN LEADERSHIP
PROVEN EXPERIENCE
PROVEN RESULTS
[X] ICN's nominees bring decades of international and pharmaceutical
experience
[X] ICN management has delivered long term financial results
ICN BEATS PEER GROUP ICN BEATS TOP 10 PHARMAS
COMPANY NAME STOCK 1 YEAR COMPANY NAME STOCK 1 YEAR
------------ SYMBOL RETURN ------------ SYMBOL RETURN
------ ------ ------ ------
Best performers... Best performers...
-------------------------------------- ----------------------------------
ICN Pharmaceuticals ICN 30.37% ICN Pharmaceuticals ICN 30.37%
-------------------------------------- ----------------------------------
Barr Labs BRL 24.24% Mylan MYL 21.75%
King Pharmaceuticals KG 19.54% Wyeth WYE 18.04%
Roche Holdings RHHBY 8.31% Abbott Labs ABT 15.23%
Amgen AMGN 4.70% Novartis AG-ADR NVS 3.39%
Enzon Inc. ENZN -1.85% Pfizer Inc. PFE 3.14%
Schering-Plough SGP -10.18% Eli Lilly & Co. LLY 2.46%
Andrx Group ADRX -21.05% Pharmacia Corp. PHA -7.37%
Watson Pharmaceuticals WPI -46.77% Biogen Inc. BGEN -20.23%
Merck & Co. MRK -20.82%
Bristol Myers Squibb BMY -25.43%
Source: Bloomberg, 4/2/01 - 3/28/02 Source: Bloomberg, 4/2/01 - 3/28/02
-----------------------------------VERSUS-------------------------------------
THE DISSIDENT SHAREHOLDERS
NO EXPERIENCE
NO LONG TERM STRATEGY
[X] Zero experience in managing a global pharmaceutical company
[X] Zero track record in complicated world of scientific discovery
[X] Ill-defined overall objectives
[X] Recent shareholders
Vote for Proven Performance. [LOGO - ICN] Vote ICN Nominees.
VOTE THE ICN GOLD CARD
---------
If you have any questions or need assistance voting your shares,
please call:
MORROW & CO., INC.
Call 1-800-607-0088